Do patients with neurogenic bladder treated with clean intermittent catheterization need antibacterial prophylaxis?

Simple item page
dc.contributor.authorAkil İ.
dc.contributor.authorÖzen Ç.
dc.contributor.authorCengiz B.
dc.date.accessioned2024-07-22T08:12:18Z
dc.date.available2024-07-22T08:12:18Z
dc.date.issued2016
dc.description.abstractBackground/aim: In this study, we investigated the effectiveness of antibiotic prophylaxis (ABP) with respect to the incidence of symptomatic urinary tract infections (UTIs) and evaluated the development of renal scarring in patients treated with clean intermittent catheterization (CIC). Materials and methods: A total of 22 patients were included in the study. The patients were administered ABP in the first year (the ABP-received period) but not in the second year (the ABP-discontinued period). Results: Twenty-eight of all cultures taken in the ABP-received period (18.2%) and 25 (16.2%) of the ABP-discontinued cultures were considered to be indicative of symptomatic UTIs (P = 0.65). The multiple antibiotic resistance rate of microorganisms in cultures taken during the ABP-discontinued period (47; 30.5%) was lower than that in those taken in the ABP-received period (62; 40.3%), (P = 0.07). There was no difference between the ABP-received and ABP-discontinued periods with respect to the development of new lesions according to dimercaptosuccinic acid results (P = 0.14). Conclusion: Routine ABP usage is not protective against the development of symptomatic UTIs and new lesions in neurogenic bladder patients receiving CIC. Furthermore, the growth of resistant microorganisms increased in the ABP-received period. © TÜBİTAK.
dc.identifier.DOI-ID10.3906/sag-1505-23
dc.identifier.issn13000144
dc.identifier.urihttp://akademikarsiv.cbu.edu.tr:4000/handle/123456789/15979
dc.language.isoEnglish
dc.publisherTurkiye Klinikleri Journal of Medical Sciences
dc.rightsAll Open Access; Bronze Open Access
dc.subjectAnti-Bacterial Agents
dc.subjectHumans
dc.subjectIntermittent Urethral Catheterization
dc.subjectUrinary Bladder, Neurogenic
dc.subjectUrinary Tract Infections
dc.subjectamoxicillin plus clavulanic acid
dc.subjectampicillin
dc.subjectantiinfective agent
dc.subjectcefazolin
dc.subjectcefoxitin
dc.subjectceftazidime
dc.subjectceftriaxone
dc.subjectcefuroxime
dc.subjectcotrimoxazole
dc.subjectgentamicin
dc.subjectnitrofurantoin
dc.subjectsultamicillin
dc.subjectantiinfective agent
dc.subjectadolescent
dc.subjectadult
dc.subjectantibiotic resistance
dc.subjectArticle
dc.subjectchild
dc.subjectclinical article
dc.subjectEnterobacteriaceae
dc.subjectEscherichia coli
dc.subjectfemale
dc.subjecthuman
dc.subjectintermittent catheterization
dc.subjectKlebsiella
dc.subjectmale
dc.subjectneurogenic bladder
dc.subjectPseudomonas
dc.subjecturethral catheterization
dc.subjecturinary tract infection
dc.titleDo patients with neurogenic bladder treated with clean intermittent catheterization need antibacterial prophylaxis?
dc.typeArticle

Files

Collections

Scopus Koleksiyonu